DONATO, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 857
EU - Europa 652
AS - Asia 191
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.702
Nazione #
US - Stati Uniti d'America 855
SE - Svezia 234
IE - Irlanda 207
CN - Cina 146
DE - Germania 53
IT - Italia 44
GB - Regno Unito 35
UA - Ucraina 33
FI - Finlandia 31
IN - India 30
SG - Singapore 13
FR - Francia 6
BE - Belgio 3
CZ - Repubblica Ceca 3
CA - Canada 2
EU - Europa 2
NL - Olanda 2
IQ - Iraq 1
IR - Iran 1
RU - Federazione Russa 1
Totale 1.702
Città #
Chandler 235
Dublin 207
Nyköping 119
Jacksonville 95
Beijing 68
Ashburn 59
New York 47
Dearborn 38
Cambridge 31
Medford 31
Princeton 31
Ann Arbor 26
Des Moines 21
Boardman 18
Bremen 18
Messina 18
Pune 18
Jinan 15
Lancaster 15
San Mateo 15
Hyderabad 10
Woodbridge 9
Seattle 8
Wilmington 8
Ningbo 7
Singapore 7
Falls Church 6
Munich 6
Augusta 5
Hangzhou 5
Hebei 5
Jiaxing 5
Nanjing 5
Shenyang 5
Lentini 4
Zhengzhou 4
Brussels 3
Haikou 3
Houston 3
Lanzhou 3
Leawood 3
Los Angeles 3
Nanchang 3
Siracusa 3
Tappahannock 3
Tianjin 3
Washington 3
Fuzhou 2
Hefei 2
Montréal 2
Norwalk 2
Olomouc 2
Paris 2
Rome 2
Saint-Fons 2
Taizhou 2
Brescia 1
Brno 1
Clearwater 1
Cupertino 1
Eschweiler 1
Guangzhou 1
Kharkov 1
Taiyuan 1
Totale 1.283
Nome #
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 78
Dialysis and the Elderly: An Underestimated Problem. 76
[From oxygen to erythropoietin, as a protagonist of the skin-brain-kidney axis]. 76
The erythropoietin and regenerative medicine: a lesson from fish 71
Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. 66
Before and after preeclampsia: What biomarkers are there? 64
Fibrosis, regeneration and cancer: what is the link? 63
A new therapy for kidney injury: regeneration. 63
Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). 62
Erythropoietin and the truths of science. 62
Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle? 59
Malnutrition in the elderly patient on dialysis. 59
Down with the erythropoietin. Long live the erythropoietin! 58
Renal complications in oncohematologic patients. 56
Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. 55
"Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL. 55
[Erythropoietin: pleiotropic actions]. 53
From chronic kidney disease to transplantation: the roles of obestatin. 53
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage 52
Apelin, Plasmatic Osmolality and Hypotension in Dialyzed Patients. 52
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. 51
From water to aquaretics: a legendary route. 49
Levels of neutrophil gelatinase-associated lipocalin in 2 patients with crush syndrome after a mudslide. 49
Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. 46
A Biotechnological T-Shirt Monitors the Patient's Heart during Hemodialysis. 45
Obestatin: a new element for mineral metabolism and inflammation in patients on hemodialysis. 43
Regenerative medicine: does Erythropoietin have a role? 43
Proteinuric effect of transcranial magnetic stimulation in healthy subjects and diabetic patients with stage 3-4 CKD 40
NGAL is a precocious marker of therapeutic response. 39
Obestatin: an interesting but controversial gut hormone. 39
NGAL as an early biomarker of kidney disease in Joubert syndrome: three brothers compared. 39
Totale 1.716
Categoria #
all - tutte 6.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.784


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020208 13 5 3 5 1 41 32 18 2 50 37 1
2020/2021187 25 4 44 14 11 23 1 5 1 26 21 12
2021/2022245 3 30 0 15 17 4 14 10 2 53 21 76
2022/2023700 49 93 37 60 66 65 3 46 261 4 11 5
2023/2024207 11 19 4 18 20 95 4 7 0 13 1 15
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 1.716